Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00300339
Status:
COMPLETED
Last Update Posted:
2008-12-19
First Post:
2006-03-07
Brief Title:
Mixed Antagonist of Serotonin for Claudication Optimal Therapy
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Double-Blind Double-Dummy Randomized Parallel Group Trial of SL650472 Three Dose Regimens Versus Placebo and Cilostazol for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MASCOT
Brief Summary:
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity by comparing three doses of SL650472 to placebo and to calibrate such effect versus cilostazol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None